Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of GP681 in Hepatic Impairment
NCT05814926Phase 1Completed
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Start
- Apr 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of suraxavir marboxil in influenza (3 arms), sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd. Primary endpoints: Peak Plasma Concentration, Area Under the Concentration-Time Curve from 0 to Last Quantifiable Concentration and 1 more. Started Apr 2023; status: completed.
02
Drugs
suraxavir marboxil
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05814926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05814926.